Gainers

• Amylyx Pharmaceuticals (NASDAQ:AMLX) stock increased by 27.5% to $27.32 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.3 billion.
• bioAffinity Technologies (NASDAQ:BIAF) shares increased by 25.28% to $0.49. The company's market cap stands at $3.1 million.
• China SXT Pharmaceuticals (NASDAQ:SXTC) stock moved upwards by 22.93% to $4.61. The market value of their outstanding shares is at $2.0 million.
• YD Bio (NASDAQ:YDES) shares increased by 15.13% to $3.88. The company's market cap stands at $238.7 million.
• Apollomics (NASDAQ:APLM) stock increased by 11.25% to $26.2. The market value of their outstanding shares is at $68.2 million.
• Haemonetics (NYSE:HAE) stock moved upwards by 10.74% to $99.97. The company's market cap stands at $4.1 billion.

Losers

• DocGo (NASDAQ:DCGO) stock fell 16.2% to $0.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $70.1 million. The company's, Q2 earnings came out yesterday.
• Apimeds Pharmaceuticals (AMEX:APUS) stock decreased by 12.39% to $3.75. The market value of their outstanding shares is at $6.4 million. As per the news, the Q2 earnings report came out 2 days ago.
• Jin Medical International (NASDAQ:ZJYL) stock declined by 11.28% to $3.07. The company's market cap stands at $27.0 million.
• Psyence Biomedical (NASDAQ:PBM) shares fell 10.81% to $3.22. The company's market cap stands at $13.7 million.
• Modular Medical (NASDAQ:MODD) shares decreased by 8.02% to $2.18. The market value of their outstanding shares is at $12.8 million. The company's, Q1 earnings came out 2 days ago.
• Pomdoctor (NASDAQ:POM) stock decreased by 7.98% to $0.81. The market value of their outstanding shares is at $104.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.